Showing 8111-8120 of 8647 results for "".
- Strategies for Slowing Myopia Progression in Kids Differ Widely Between Ophthalmologistshttps://modernod.com/news/strategies-for-slowing-myopia-progression-in-kids-differ-widely-between-ophthalmologists/2476919/The strategies for slowing myopia progression differ widely among pediatric ophthalmologists around the world and include both effective and ineffective approaches, according to an online survey, as reported by Reuters. Dr. Eedy Mez
- Nicox Completes Enrollment of NCX 4251 Phase 2 Trial with Topline Results on Track for Q4 2019https://modernod.com/news/nicox-completes-enrolment-of-ncx-4251-phase-2-trial-with-top-line-results-on-track-for-q4-2019/2476918/Nicox SA announced that it has completed enrollment in its multicenter, dose escalating, US phase 2 clinical trial evaluating the safety and tolerability of NCX 4251 in acute exacerbations of blepharitis. The primary objective of this
- Pharmaceutical Companies Face Steeper Price Cuts in China as Country Expands Drug Bulk-Buying Scheme Nationwidehttps://modernod.com/news/pharmaceutical-companies-face-steeper-price-cuts-in-china-as-country-expands-drug-bulk-buying-scheme-nationwide/2476915/China has expanded across the country a drug procurement program aimed at reducing the cost of generic medicines, a move that may force global pharmaceutical firms to slash their prices by half in order to maintain sales to the country’s public hospitals, Bloomberg
- Eversight to Offer Preloaded DMEK in DORC Tubehttps://modernod.com/news/eversight-first-to-offer-preloaded-dmek-in-dorc-tube/2476911/Eversight announced it is the first eye bank to prepare preloaded Descemet membrane endothelial keratoplasty (DMEK) tissue in the Melles DORC tube, offering corneal surgeons more preloaded tissue options that further streamline surgeries and reduce cost, according to a company news release. <
- Cataract Surgery Products Continue to be the Main Single-Use Surgical Device Sales Driverhttps://modernod.com/news/cataract-surgery-products-continue-to-be-the-main-single-use-surgical-device-sales-driver/2476905/The world’s aging population—leading to steady growth in cataract surgeries—and rising concerns over cross-contamination are key factors that will drive healthy growth in the single-use ophthalmic surgical product mar
- Boehringer Ingelheim Partners with Inflammasome Therapeutics to Develop Novel Therapies for Patients with Retinal Diseaseshttps://modernod.com/news/boehringer-ingelheim-partners-with-inflammasome-therapeutics-to-develop-novel-therapies-for-patients-with-retinal-diseases/2476903/Boehringer Ingelheim and Inflammasome Therapeutics announced they have entered into a co-development and license agreement to develop up to three therapies for patients with retinal diseases. By combining Inflammasome’s unique intravitreal (IVT) drug delivery technologies with Boehringer Ingelhei
- US House Speaker Nancy Pelosi Introduces Plan to Permit Price Negotiation for Some Drugshttps://modernod.com/news/us-house-speaker-nancy-pelosi-introduces-plan-to-permit-price-negotiation-for-some-drugs/2476901/US House Speaker Nancy Pelosi on Thursday unveiled proposed legislation that would permit the federal government to negotiate prices of drugs for Medicare and other health programs. Specifically, the proposal would empower the Department of Health and Human Services (HHS) to annually ne
- Eye Cancer Researchers at Bascom Palmer and Sylvester Identify Function of Key Tumor Suppressorhttps://modernod.com/news/eye-cancer-researchers-at-bascom-palmer-and-sylvester-identify-function-of-key-tumor-suppressor/2476900/Cancer cells remember things they shouldn’t. During development, stem and progenitor cells move freely through the body as they differentiate into heart, brain, liver, and eyes. But after humans are born, that process should stop. Cells shouldn’t travel or change anymore; they should stay put and
- Graybug Vision Initiates Clinical Trial in Macular Edema Secondary to DME or RVOhttps://modernod.com/news/graybug-vision-initiates-clinical-trial-in-macular-edema-secondary-to-dme-or-rvo/2476898/Graybug Vision announced the initiation of its phase 2a study with GB-102 in patients with macular edema (ME) secondary to diabetic macular edema (DME) or retinal vein occlusion (RVO). GB-102, a pan-Vascular Endothelial Growth Factor (VEGF) inhibitor and potential twice-per-year therapy is
- Oyster Point Pharma Expands Executive Leadership Teamhttps://modernod.com/news/oyster-point-pharma-expands-executive-leadership-team/2476896/Oyster Point Pharma announced the appointment of Dan Lochner, MBA, as its Chief Financial Officer, and John Snisarenko, MBA, as Chief Commercial Officer. Mr. Lochner joins Oyster Point Pharma after spending nearly 15 years, most recently as a Managing Director, at Goldman Sachs asset mana